You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Monday<br />
March 4 Oral Sessions<br />
Session 12 CROI <strong>2013</strong><br />
973 Pharmacokinetics of Tenofovir in Thai Adolescents<br />
Using Ritonavir-boosted Protease Inhibitor-based<br />
Regimens<br />
Wasana Prasitsuebsai* 1 , S Kerr 1,2 , N Thammajaruk 1 , A Colbers 3 ,<br />
S Keadpudsa 1 , T Chuanjaroen 1 , M Gorowara 1 , D Burger 3 , A Sohn 4 ,<br />
and J Ananworanich 1,5<br />
1 HIV-NAT Res Collaboration, Thai Red Cross AIDS Res Ctr, Bangkok;;<br />
2 Kirby Inst, Univ of New South Wales, Sydney, Australia;; 3 Radboud Univ<br />
Nijmegen Med Ctr, The Netherlands;; 4 TREAT Asia/amfAR-Fndn for AIDS<br />
Res, Bangkok, Thailand;; and 5 SEARCH, Thai Red Cross AIDS Res Ctr,<br />
Bangkok<br />
b Monday, 1:30-2:30 pm; B308<br />
Session 13–Themed Discussion & Scientific Overview<br />
(see Session 99 on Tuesday for corresponding Poster Abstracts)<br />
New Approaches to ARV Drug Delivery<br />
Discussants:<br />
Marta Boffito, Chelsea and Westminster Hosp, London, UK<br />
Kimberly Struble, FDA, Silver Spring, MD, US<br />
511<br />
Challenges and Opportunities for the<br />
Development of Long-acting ARVs<br />
������������<br />
Chelsea and Westminster Hosp, London, UK<br />
512a Improved Biodistribution, Pharmacokinetics, and<br />
ARV Responses for Folate-targeted Nanoformulated<br />
ART<br />
Pavan Puligujja*, H Gendelman, L Kendrick, N Smith, S Balkundi,<br />
U Roy, R Veerubhotla, J McMillan, and X Liu<br />
Univ of Nebraska Med Ctr, Omaha, US<br />
512b Development of Small Magnetite ARV Nanoparticles<br />
for Targeted Drug Delivery to Viral Reservoirs<br />
Dongwei Guo*, T Li, J McMillan, M Boska, X Liu, and H Gendelman<br />
Univ of Nebraska Med Ctr, Omaha, US<br />
513 Enhanced Pharmacological Properties of Efavirenz<br />
Formulated as Solid Drug Nanoparticles<br />
P Martin 1 , Neill Liptrott* 1 , T McDonald 1 , M Giardiello 1 , P Roberts 1 ,<br />
P Curley 1 , D Smith 2 , M Siccardi 1 , S Rannard 1 , and A Owen 1<br />
1 Univ of Liverpool, UK and 2 Univ of Northumbria, Newcastle Upon Tyne, UK<br />
Concluding Comments: The Regulatory Pathway for<br />
Development of Long-acting ARVs<br />
Kimberly Struble FDA, Silver Spring, MD, US<br />
b Monday, 1:30-2:30 pm; B313<br />
Session 14–Themed Discussion<br />
(see Session 186 on Tuesday for corresponding Poster Abstracts)<br />
Implementation and Cost-effectiveness of Male<br />
Circumcision<br />
Discussants:<br />
Connie Celum, Univ of Washington, Seattle, US<br />
Kenneth Freedberg, Massachusetts Gen Hosp, Boston, US (invited)<br />
1007 Shang Ring vs Forceps-guided Adult Male Circumcision,<br />
a Randomized Controlled Effectiveness Study: Western<br />
Uganda<br />
Samuel Kanyago* 1,2 , D Riding 1,3 , E Mutakooha 1 , A Lopez 1 , and M Siedner 4<br />
1 Mbarara Univ of Sci and Tech, Uganda;; 2 Good Shepherd Hosp, Siteki,<br />
Swaziland;; 3 Northwest Deanery, Manchester, UK;; and 4 Massachusetts Gen<br />
Hosp Ctr for Global Hlth, Boston, US<br />
1008 Factors Associated with Voluntary Medical Male<br />
Circumcision Adverse Events: Nyanza Province, Kenya<br />
Kipruto Chesang* 1 , Z Mwandi 1 , S Mwalili 1 , P Cherutich 2 , A Ochieng 2 ,<br />
P Oyaro 3 , G Otieno 4 , K Serrem 5 , D Odera 6 , and A Kim 1<br />
1 CDC, Ctr for Global Hlth, Nairobi, Kenya;; 2 Natl AIDS and STD Control<br />
Prgm, Kenya Ministry of Publ Hlth and Sanitation, Nairobi;; 3 Kenya Med<br />
Res Inst, Nairobi;; 4 Nyanza Reproductive Hlth Society, Kisumu, Kenya;;<br />
5 Catholic Med Mission Board, Nairobi, Kenya;; and 6 Impact Res and Devt<br />
Org, Kisumu, Kenya<br />
1009 Male Circumcision Coverage by Risk Profiles:<br />
Rakai, Uganda<br />
Xiangrong Kong* 1 , A Ndyanabo 2 , G Kigozi 2 , F Nalugoda 2 , D Serwadda 3 ,<br />
M Wawer 1 , R Gray 1 , and Rakai Hlth Sci Prgm<br />
1 Johns Hopkins Univ, Baltimore, MD, US;; 2 Rakai Hlth Sci Prgm, Kalisizo,<br />
Uganda;; and 3 Makerere Univ, Kampala, Uganda<br />
6 � 20th Conference on Retroviruses and Opportunistic Infections<br />
1010 Costs and Effectiveness of Male Circumcision<br />
Scale-up for the Prevention of HIV and Other<br />
Sexually Transmitted Infections: Sub-Saharan Africa<br />
Seema Kacker* 1 , K Frick 2 , T Quinn 1,3 , R Gray 2 , and A Tobian 1<br />
1 Johns Hopkins Univ Sch of Med, Baltimore, MD, US;; 2 Johns Hopkins<br />
Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US;; and 3 NIAID, NIH,<br />
Bethesda, MD, US<br />
1011 Uptake of Neonatal Male Circumcision as Part of HIV<br />
Prevention Efforts in Botswana: Maternal Motivators<br />
and Barriers<br />
Rebeca Plank* 1,2,3 , K Wirth 2,3 , N Ndubuka 3 , P Kebaabetswe 4 , C Lesetedi 5 ,<br />
J Makhema 3 , D Halperin 6 , R Shapiro 2,3,7 , M Mmalane 3 , and S Lockman 1,2,3<br />
1 Brigham and Women�s Hosp;; 2 Harvard Sch of Publ Hlth;; 3 Botswana-<br />
Harvard Partnership;; 4 Univ of Botswana, Sch of Med;; 5 Botswana<br />
Ministry of Hlth;; 6 Univ of North Carolina at Chapel Hill;; and 7 Beth Israel<br />
Deaconess Med Ctr<br />
b Monday, 1:30-2:30 pm; Ballroom 3-4<br />
Session 15–Themed Discussion<br />
(see Session 80 on Tuesday for corresponding Poster Abstracts)<br />
What Is Latency and What Can We Do about It?<br />
Discussants:<br />
Mary Kearney, Ctr for Cancer Res, NCI, NIH, Frederick, MD, US<br />
Robert Siliciano, Johns Hopkins Univ Sch of Med, Baltimore, MD, US<br />
371 Only a Small Fraction of HIV-1 Proviruses in Resting<br />
CD4 + T Cells Can Be Induced to Produce Virions<br />
ex vivo with Anti-CD3/CD28 or Vorinostat<br />
Anthony Cillo* 1 , M Sobolewski1 , J Coffin2 , and J Mellors1 1 2 Univ of Pittsburgh, PA, US and Tufts Univ, Boston, MA, US<br />
372 A Comparison of Methods Used to Measure Rectal<br />
HIV Levels Suggests that HIV DNA Resides in Cells<br />
Other than CD4 + T Cells, Including CD45 + CD13 + Cells<br />
Steven Yukl* 1,2 , H Hatano2,3 , L Epling2,3 , P Hunt2,3 , P Li1,2 , D Havlir2,3 ,<br />
M Somsouk2,3 , E Sinclair2,3 , S Deeks2,3 , J Wong1,2 , and DARE<br />
1 2 San Francisco VAMC, CA, US;; Univ of California, San Francisco, US;;<br />
and 3San Francisco Gen Hosp, CA, US<br />
373 Integrated HIV DNA and Associated Histiocyte<br />
Marker mRNA in Autopsy Samples of Non-lymphoid<br />
Tissue Including the Central Nervous System<br />
Benjamin Gelman* 1 , T Chen1 , J Lisinicchia1 , and A Rice2 1 2 Univ of Texas Med Branch, Galveston, US and Baylor Coll of Med,<br />
Houston, TX, US<br />
374 HIV Preferentially Infects Hematopoietic Progenitor<br />
Cells with High CD4 and Can Be Found in CD133 +<br />
Hematopoietic Progenitor Cells in a Subset of<br />
Optimally Treated People with Long-term Viral<br />
Suppression<br />
Lucy McNamara*, N Sebastian, A Onafuwa-Nuga, J Riddell,<br />
D Bixby, and K Collins<br />
Univ of Michigan, Ann Arbor, US<br />
375 Differences in Integration Site Distributions for<br />
Latent and Expressed HIV-1 Proviruses<br />
Scott Sherrill-Mix*, K Ocwieja, N Malani, U O’Doherty,<br />
and F Bushman<br />
Univ of Pennsylvania, Philadelphia, US<br />
376 Histone Deacetylase Inhibitor Romidepsin Induces<br />
HIV in CD4 + T Cells from ART-suppressed Subjects<br />
at Concentrations Achieved by Clinical Dosing<br />
George Wei* 1 , V Chiang1 , E Fyne2 , M Balakrishnan1 , G Stepan1 , A Tsai1 ,<br />
J Lalezari3 , J Mellors2 , R Geleziunas1 , and T Cihlar1 1 2 Gilead Sci Inc, Foster City, CA, US;; Univ of Pittsburgh Sch of Med, PA,<br />
US;; and 3Quest Clin Res, San Francisco, CA, US
Change language